Week In Review: IHH Building $1 Billion Of China Hospitals; Seeks Deals For More

Malaysia's IHH Healthcare is building four China hospitals, a $1 billion investment, and it is looking for more, possibly through M&A deals; Australia's CSL Limited will pay $352 million to acquire an 80% controlling stake in China blood products company Ruide; WuXi Biologics rose 37% in the first day of Hong Kong trading following its $511 million IPO; Athenex, a US-China cancer biopharma, completed a $66 million IPO on the NASDAQ exchange; BeauCare Clinics, a Beijing aesthetic surgery clinic chain, raised $29 million in a Series B funding; Evasc Neurovascular of Canada closed a $7.5 million Series A round, led by Shanghai's Yonghua Capital; Lee's Pharm of Hong Kong in-licensed Asia rights to respiratory disease treatments from US-based Windtree in a $40 million deal; Venus Medtech of Hangzhou acquired InterValve, a US maker of transcatheter aortic valve devices; Sihuan Pharma formed a JV to distribute aesthetic products from Austria's Croma-Pharma; ACEA Biosciences, a San Diego-Hangzhou company, completed a successful Phase I trial of a novel BTK inhibitor; and Hutchison China MediTech announced the CFDA accepted a NDA for its lead drug, the cancer treatment fruquintinib.